Interleukin Inhibitors Market Is Estimated To Witness High Growth Owing To Rising Cancer Incidences

The Interleukin Inhibitors Market is estimated to be valued at USD 36.60 Bn in 2024 and is expected to exhibit a CAGR of 12.6% over the forecast period 2024- 2031, as highlighted in a new report published by Coherent Market Insights.

The increasing prevalence of cancer and autoimmune diseases is expected to drive the growth of the interleukin inhibitors market during the forecast period. According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide and cancer will account for nearly 10 million deaths by 2020, and myeloma is expected to drive the market growth. In addition, research and development activities are underway to develop new drugs to treat other chronic diseases using interleukin inhibitors it is expected to provide income-generating opportunities to market players in the near future.

Key Market Trends:

Increasing number of clinical trials evaluating efficacy of interleukin inhibitors in treating other disease conditions is a major trend witnessed in the interleukin inhibitors market. For instance, in December 2020, results from a Phase 1b clinical trial evaluating efficacy and safety of nesilizumab (inhibitor of interleukin-6) in combination with veltuzumab for treatment of severe COVID-19 were published in The Lancet Rheumatology journal. Furthermore, rising focus of key players on developing cost-effective biosimilar versions of blockbuster interleukin inhibitor drugs to expand their consumer base in emerging economies will aid the market growth over the forecast period. More coverage can be found in the sample copy.

Cryopreservation Market Opportunity

With more women choosing to delay starting a family, the demand for egg freezing services has grown significantly. Egg freezing allows women to preserve their current reproductive potential and provide them more time and flexibility with family planning. It is a major opportunity for cryopreservation market players to tap into. Various fertility clinics now offer egg freezing services to women of all ages. The process involves extracting eggs from a woman’s ovaries and freezing them for future use via in-vitro fertilization (IVF) when she is ready to conceive. The ability to freeze and store reproductive cells like eggs and sperm has helped increase acceptance for this technology.

As regenerative therapies using stem cells gain more recognition, private and public stem cell banking is rising. Stem cell banking involves collecting, processing, testing, cryopreserving and storing stem cells from sources like umbilical cord blood and tissue. These stem cells can then be used for a person’s medical treatments in future if they fall ill. With no cure for many life-threatening diseases currently, stem cell banking provides hope. It is thus a fast growing segment within the cryopreservation market. Both private and public banks are offering various stem cell storage plans tailored for families and individuals.

Key Cryopreservation Market Takeaways

The global cryopreservation market is anticipated to witness a CAGR of 16.1% during the forecast period 2024-2031, owing to the rising demand for fertility preservation and regenerative medicine advancements.

By Type, the sperm banking segment is expected to hold a dominant position, accounting for over 35% share of the cryopreservation market by 2031 due to the widespread usage of cryopreserved sperm in assisted reproduction techniques.

By Route of Administration, the stem cell based therapies segment will grow the fastest at a CAGR of 17.8% during the forecast period. This is attributed to the expanding clinical applications of mesenchymal stem cells (MSCs) in treating various diseases.

Regionally, North America is dominating the cryopreservation market and is projected to maintain its lead, accounting for over 40% share by 2031. This growth can be attributed to the availability of advanced fertility treatments and regenerative medicine in the region.

Competitor Insights:

AbbVie Inc
Johnson and Johson
UCB S.A
Cryo-Save AG
Thermo Fisher Scientific
Charles River
General Electric among

Recent Developments in Interleukin Inhibitors Market

Recent developments in off-market interleukin inhibitors In June 2023, Theravance Biopharma reported positive results from a Phase 2 study evaluating isencitinib which is an interleukin-13 inhibitor Oral form in patients with ulcerative colitis The treatment showed significantly improved rates of clinical remission and endoscopic healing at week 12 compared to placebo. From these results The Company plans to initiate two additional Phase 3 trials by the end of 2023 to support regulatory approval.

In July, AbbVie released interim data from a Phase 3 trial of upadacitinibe (Rinvoq), an oral Janus kinase (JAK) inhibitor, in AR patients who had an incomplete response to TNF inhibitors such as Humira. Upadacitinib was seen to significantly improve patients’ ACR50 response compared to placebo at week 12. Upadacitinib is already approved for AR, so these new data could support expanding its use to a broader patient population. Full coverage of the report available here.